A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
Eligibility criteria
Qualifiers
Are on stable incretin therapy at screening
≥30 kg/m2 OR
hypertension
dyslipidemia
Disqualifiers
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
dipeptidyl peptidase-4 (DPP-4) inhibitors
Trial design
Treatments tested in this trial
- Eloralintide
- Placebo
Treatment groups
900 Participants
are divided into 5 treatment groupsLocations
183Australia
Emeritus Research2019, Botany Australia
Box Hill Hospital3128, Box Hill Australia
Royal Brisbane and Women's Hospital4029, Brisbane Australia
Emeritus Research3124, Camberwell Australia
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov